Entity

Time filter

Source Type

Incheon, South Korea

Cho Y.-Y.,Kyungpook National University | Baek N.-I.,Kyung Hee University | Chung H.-G.,GangHwa Agricultural R and nter | Jeong T.-S.,Korea Research Institute of Bioscience and Biotechnology | And 5 more authors.
European Journal of Integrative Medicine | Year: 2012

Introduction: Alternative complementary therapy with medicinal herbs may help restore normal fasting glycemia in pre-diabetes and therefore delay or prevent T2D. The aim of this randomized controlled trial was to assess the efficacy of Sajabalssuk (Artemisia princeps Pampanini) extract to improve fasting glycemia in pre-diabetes. Methodology: Ninety-nine subjects with pre-diabetes (100. mg/dL. <. impaired fasting glucose. <. 125. mg/dL) were randomly assigned into placebo (starch, 2000. mg/day), positive-control (pinitol, 1140. mg/day), and SBE (Sajabalssuk extract 3000. mg/day) groups for 9. weeks. Primary outcomes were fasting blood glucose and HbA1c. Secondary outcomes were insulin resistance, plasma lipid profile and body composition. Dietary intake was also analyzed, and safety was assessed with plasma liver toxicology markers. Results: Nine weeks of SBE treatment significantly lowered fasting blood glucose (-16.51. ±. 2.78%, p<. 0.05) compared placebo or positive-control, effectively restoring normal fasting glycemia. Furthermore, SBE treatment significantly reduced HbA1c (-7.81. ±. 3.39%, p<. 0.05) and insulin resistance (-14.71. ±. 20.37%, p<. 0.05) compared to placebo or positive-control treatment. In addition, SBE treatment improved non-HDL-cholesterol (-11.57. ±. 3.94%, p<. 0.05) and HDL-cholesterol (10.90. ±. 4.35%, p<. 0.05) compared to placebo and positive-control. However, SBE treatment had no effect on other secondary outcomes including atherogenic biomarkers, blood pressure and body composition. Finally, plasma liver toxicology markers were unaltered by SBE treatment. Conclusions: Pre-diabetes treatment with the medicinal herb Sajabalssuk (3000. mg/day) for 9. weeks can improve fasting blood glucose, HbA1c and reduce insulin resistance. SBE treatment appears to have a secondary benefit leading to improved plasma non-HDL and HDL-cholesterol levels. In conclusion, Sajabalssuk extract may provide a useful alternative therapy for management of pre-diabetes. © 2012 Elsevier GmbH. Source


Choi J.-Y.,Kyungpook National University | Choi J.-Y.,Bio Industry Center | Shin S.-K.,Kyungpook National University | Jeon S.-M.,Kyungpook National University | And 6 more authors.
Journal of Medicinal Food | Year: 2011

Previously we reported that an ethanol extract from Artemisia princeps Pampanini lowered blood glucose in db/db mice. Here we report a preliminary study in which the blood glucose-lowering effects of two different doses of sajabalssuk ethanol extract (SBE), containing eupatilin and jaseocidin, were examined in hyperglycemic subjects with fasting blood glucose (FBG) levels of 100-150 mg/dL. Subjects were randomized into four groups: negative control (2,000 mg of lactose /day), positive control (1,140 mg of pinitol/day), low-dose SBE (2,000 mg of SBE/day), and high-dose SBE (4,000 mg of SBE/day). After 8 weeks of supplementation, FBG and glycosylated hemoglobin levels were significantly lowered in low-and high-dose SBE groups compared to the baseline values; high-dose SBE also resulted in significantly lower plasma free fatty acid levels and systolic blood pressure. This study demonstrated that supplementation of 2 g or 4 g of SBE daily can significantly reduce blood glucose in hyperglycemic subjects, although high-dose SBE seemed to be more effective than low-dose SBE for lowering plasma free fatty acid level and systolic blood pressure. © Copyright 2011, Mary Ann Liebert, Inc. and Korean Society of Food Science and Nutrition. Source


Chung K.-S.,Kyung Hee University | Choi J.-H.,Kyung Hee University | Back N.-I.,Kyung Hee University | Choi M.-S.,Kyungpook National University | And 4 more authors.
Molecular Nutrition and Food Research | Year: 2010

Although eupafolin, a flavone found in Artemisia princeps Pampanini, has been shown to inhibit the growth of several human cancer cells, its mode of action is poorly understood. In this study, we investigated the pro-apoptotic activities of eupafolin in human cervical carcinoma HeLa cells. It was found that eupafolin induced apoptosis in a dose-dependent manner, as evidenced by DNA fragmentation and the accumulation of positive cells for annexin V. In addition, eupafolin triggered the activations of caspases-3, -6, -7, -8, and -9 and the cleavages of their substrates, such as, poly (ADP-ribose) polymerase and lamin A/C. Furthermore, treatment with eupafolin resulted in a loss of mitochondrial membrane potential (ΔΨm), increased the release of cytochrome c to the cytosol, and altered the expression levels of B-cell lymphoma 2 (Bcl-2) family proteins. Interestingly, caspase-8, an initiator caspase, was activated after the loss of ΔΨm and the activations of caspases-3 and -9. Moreover, treatment with z-DEVD-fmk (a specific caspase-3 inhibitor) and the overexpression of Bcl-2 prevented eupafolin-stimulated caspase-8 activation. Altogether, these results suggest that the eupafolininduced apoptosis in HeLa cells is mediated by caspase-dependent pathways, involving caspases-3, -9, and -8, which are initiated by the Bcl-2-dependent loss of ΔΨm. © 2010 WILEY-VCH Verlag GmbH & Co. Source


Shin J.-S.,Kyung Hee University | Yun C.H.,Kyung Hee University | Chung K.-S.,Kyung Hee University | Bang M.-H.,Kyung Hee University | And 4 more authors.
Food and Chemical Toxicology | Year: 2014

This study was undertaken to investigate the anti-arthritic potential of a standardized ethyl acetate fraction from the roots of Brassica rapa (EABR) and to explore the molecular mechanisms in adjuvant-induced arthritic rats and macrophages. In AIA-induced arthritic rats, EABR significantly reduced paw swelling, an arthritic index, serum rheumatoid factor, and tissue expression ratio of RANKL/OPG versus vehicle-administered group. This was found to be well correlated with significant suppressions in productions of PGE2, NO, and pro-inflammatory cytokines and in activations of NF-κB in AIA-induced paw tissues and LPS-induced macrophages. EABR attenuated NF-κB activation by reducing the nuclear translocation and phosphorylation of the p65 NF-κB, which were accompanied by parallel reductions in the degradation and phosphorylation of IκBα after blocking the phosphorylation mediated IKK activation. The findings suggest EABR exerts its anti-arthritic and anti-inflammatory properties via NF-κB inactivation in vitro and in vivo, and that EABR is a potential therapeutic for the treatment of arthritis and inflammation-associated disorders. © 2014 Elsevier Ltd. Source

Discover hidden collaborations